A Case of Gemcitabine and Cisplatin Associated Posterior Reversible Encephalopathy Syndrome

Eun Jin Kwon; Se Won Kim; Kwang Ki Kim; Hyung Suk Seo; Do Yeun Kim

doi:10.4143/crt.2009.41.1.53

Articles

Page Path: HOME > Cancer Res Treat > Volume 41(1); 2009 > Article

Case Report A Case of Gemcitabine and Cisplatin Associated Posterior Reversible Encephalopathy Syndrome: Eun Jin Kwon, M.D.¹, Se Won Kim, M.D.¹, Kwang Ki Kim, M.D.², Hyung Suk Seo, M.D.³, Do Yeun Kim, M.D.¹; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2009;41(1):53-55.
DOI: https://doi.org/10.4143/crt.2009.41.1.53
Published online: March 31, 2009

¹Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea.

²Department of Neurology, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea.

³Department of Radiology, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea.

Correspondence: Do Yeun Kim, M.D., Ph.D. Division of Hematology & Medical Oncology Department of Internal Medicine, Dongguk University Ilsan Hospital, 814, Sicksa-dong, Ilsandong-gu, Goyang 410-773, Korea.
Tel: 82-31-961-7143, Fax: 82-31-961-7141, smdkdy@hanmail.net, smdkdy@duih.org, smdkdy6730@yahoo.co.kr

• Received: November 17, 2008 • Accepted: January 4, 2009

9,857 Views
91 Download
26 Crossref

prev next

Full Article

Download PDF

Abstract

A 58-year-old female receiving gemcitabine and cisplatin chemotherapy for stage IV gallbladder cancer developed the clinicoradiologic syndrome, posterior reversible encephalopathy syndrome (PRES). Just before the 4th gemcitabine chemotherapy cycle, she was admitted to the hospital with complaints of headache, dizziness, and generalized tonic-clonic seizures. A MRI was performed on the day when the seizure developed, and the findings showed patchy cortical and subcortical T2 hyperintensity without enhancement that involved both occipital and parietal lobes. Phenytoin loading and maintenance was started for prevention of recurrent seizures, which was successful. The follow-up brain MRI obtained 10 days after the seizure attack showed completely resolved radiologic findings. After the MRI findings revealed complete resolution, phenytoin maintenance was stopped. Even with discontinuation of phenytoin, she had no seizures or other clinical manifestations.
Key words: Cisplatin, Gemcitabine, Posterior reversible encephalopathy syndrome (PRES)

Introduction

Posterior reversible encephalopathy syndrome (PRES) is a reversible clinicoradiologic syndrome which presents with headaches, seizures, loss of vision, and altered mental status with typical imaging revealing primary involvement of the bilateral parietal-occipital lobes (1). Although the pathogenesis remains poorly understood, hypertensive encephalopathy, pre-eclampsia, eclampsia, renal failure, general anesthesia, and several immunosuppressant agents are known etiologic causes (1-4). Recently, several chemotherapeutic agents, such as cisplatin (5), cytarabine (6), and gemcitabine (7,8) have also been shown to cause PRES, thus physicians who are involved with chemotherapeutic agents need to manage patients with neurotoxicity related to chemotherapeutic agents. A few cases have been reported for chemotherapeutic agent-related PRES in Korea, but PRES is still uncommon (9-11). Herein we describe a patient who experienced PRES while receiving gemcitabine and cisplatin combination chemotherapy for gallbladder cancer.

Case Report

A 58-year-old woman was diagnosed with gallbladder cancer had hepatic and regional lymph node metastases. Palliative capecitabine chemotherapy was begun; however, the disease progressed with aggravated lung metastases during the 2nd cycle. The chemotherapy regimen was changed to gemcitabine (1,200 mg/m² on days 1 and 8 of each 21-day cycle) and cisplatin (60 mg/m² on day 1 of each 21-day cycle). Her performance status remained excellent. Two weeks after the 3rd cycle of chemotherapy, she was admitted with the sudden onset of headaches, dizziness, and generalized tonic-clonic seizures. At that time, her blood pressure was 170/90 mmHg, while her blood pressure was 100~150/50~80 mmHg during previous hospitalizations. A head computed tomography was obtained initially, which showed focal low density in both occipital lobes without any evidence of brain metastasis.

Brain magnetic resonance imaging (MRI; T2 and fluid-attenuated inversion recovery [FLAIR] image sequences) was obtained and revealed patchy cortical and subcortical T2 hyperintensity without enhancement, apparent on both occipital and parietal lobes (Fig. 1). The clinicoradiographic diagnosis was consistent with posterior reversible encephalopahty syndrome (PRES). With phenytoin loading and maintenance therapy, her mental status gradually normalized. A follow-up MRI obtained 10 days after the seizure attack showed completely resolved radiologic findings, which was consistent with the diagnosis of PRES (Fig. 2). While receiving supportive care during the hospital stay, she received no more chemotherapy. With improved cognition, she was discharged from the hospital, but approximately 1 month after discharge, she ultimately succumbed of cancer progression.

Discussion

PRES is a clinicoradiologic entity characterized by headaches, altered mental status, seizures, and visual loss. PRES was first described by Hinchey et al. (1) in 1996. He offered the term reversible posterior leukoencephalopathy syndrome (RPLS) for a series of patients who presented with headaches, altered mental status, seizures, and loss of vision, and radiologic findings of reversible symmetric posterior cerebral white-matter abnormalities on CT and MRI. Although the pathogenesis remains unclear, several conditions, including hypertensive encephalopathy, pre-eclampsia/eclampsia, renal failure, general anesthesia, immunosuppressants, and cytotoxic agents (1-8), have been shown to cause PRES. The suggested pathophysiologic mechanisms are cerebral vasospasm with resulting ischemia within the involved territories and a breakdown in cerebrovascular autoregulation with ensuing interstitial extravasation of fluid (12). Radiographic and clinical findings are typically reversible within 2 weeks after correction of the precipitating event. Otherwise, persistent neurologic defects may occur with progression to infarction, hemorrhage, or death.

A recent study reviewed the 22 Korean cases who presented with PRES (13). Pre-eclampsia was the leading cause of PRES, followed by immunosuppressants, renal failure, and migraine. With respect to chemotherapeutic agent-associated PRES, a few cases of leukoencephalopathy associated with 5-FU, cisplatin, and cytarabine have been reported in Korea (9-11).

Gemcitabine-associated PRES was first identified in 2001 (7). After this, a few reports followed and the authors suggested neurotoxicity of gemcitabine by showing that PRES re-developed after re-administration of gemcitabine (8,14). Although the precise mechanism of PRES by chemotherapeutic agents, such as cisplatin, cytarabine, gemcitabine, interferon-a, rituximab, or sorafenib remains unclear, the brain-capillary leak syndrome related to hypertension or direct CNS microvascular injury has been suspected (4-8,15). With respect to the cisplatin-induced encephalopathy, hypomagnesemia has been suggested to be a contributing factor for PRES (5).

Gemcitabine and/or cisplatin are commonly used drugs in many solid cancers. We hereby present PRES from frequently used chemotherapeutic drugs. The time to onset of PRES by those agents can be within several hours to 3 months after repeated infusion. Because our patient received the combination chemotherapy with gemcitabine and cisplatin, no one can be certain about which agent was the main causative factor of PRES.

PRES is reversible with discontinuation of causative agents and supportive management; however, if undetected, PRES may lead to permanent neurologic damage or death. Thus, increasing awareness of PRES is needed in patients who undergo chemotherapy with those agents. Further investigations into the mechanisms of toxicity and risk factors of PRES caused by chemotherapy are required to prevent unexpected complications.

REFERENCES

1. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494–500. PMID: 8559202Article PubMed
2. Rangi PS, Partridge WJ, Newlands ES, Waldman AD. Posterior reversible encephalopathy syndrome: A possible late interaction between cytotoxic agents and general anesthesia. Neuroradiology. 2005;47:586–590. PMID: 15997391Article PubMed
3. Irvin W, MacDonald G, Smith JK, Kim WY. Dexamethasone-induced posterior reversible syndrome. J Clin Oncol. 2007;25:2484–2486. PMID: 17557962Article PubMed
4. Beck WT, Kuttesch JF. Neurological symptoms associated with cyclosporin plus doxorubicin. Lancet. 1992;340:496PMID: 1354830Article
5. Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol. 1998;19:415–417. PMID: 9541291PubMed PMC
6. Baker WJ, Royer GL Jr, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol. 1991;9:679–693. PMID: 1648599Article PubMed
7. Russell MT, Nassif AS, Cacayorin ED, Awwad E, Perman W, Dunphy F. Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings. Magn Reson Imaging. 2001;19:129–132. PMID: 11295355Article PubMed
8. Rajasekhar A, George TJ Jr. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: A case report and review of literature. Oncologist. 2007;12:1332–1335. PMID: 18055853Article PubMed
9. Cho SG, Moon H, Lee JH, Lee SY, Kim CC, Lee KS. Behenoyl cytarabine-associated reversible encephalopathy in a patient with acute myelogenous leukemia. J Korean Med Sci. 1999;14:89–92. PMID: 10102531Article PubMed PMC
10. Choi SM, Lee SH, Yang YS, Kim BC, Kim MK, Cho KH. 5-Fluorouracil-induced leukoencephalopathy in patients with breast cancer. J Korean Med Sci. 2001;16:328–334. PMID: 11410695Article PubMed PMC
11. Kim GH, Cho TH, Park JY, Chung YG, Lee KC, Lee HK. Leukoencephalopathy Associated with 5-Fluorouracil and Cisplatin Therapy. J Korean Neurosurg Soc. 1996;25:622–626.
12. Port JD, Beauchamp NJ Jr. Reversible intracerebral pathologic entities mediated by vascular autoregulatory dysfunction. Radiographics. 1998;18:353–367. PMID: 9536483Article PubMed
13. Lee EJ, Song CJ, Yu WJ, Ahn KJ, Jung SL, Lee YS, et al. Reversible Posterior Leukoencephalopathy Syndrome. J Korean Radiol Soc. 2001;45:339–346. Article
14. Larsen FO, Hansen SW. Severe neurotoxicity caused by gemcitabine treatment. Acta Oncol. 2004;43:590–591. PMID: 15370618Article PubMed
15. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol. 2006;24:e48PMID: 17008686Article PubMed

Fig. 1

Patchy cortical and subcortical T2 hyperintensity without enhancement, bilateral occipital and parietal lobes (on the day of seizure attack [7/31/2008]).

Fig. 2

Improved state of patchy cortical and subcortical T2 hyperintensity without enhancement since 7/31/2008, bilateral occipital and parietal lobes (10 days after seizure attack [8/11/2008]). (on the day of seizure attack [7/31/2008]).

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Newly identified adverse events for gemcitabine using the Food and Drug Administration Adverse Event Reporting System
Wei Zhang, Yuhong Wang, Xin Jiang, Hu Zhao, Xinli Jia, Qiye Wang, Yue Chen, Yuanfang Jiang, Zhifang Ma, Lina Chang, Xin Wang
Expert Opinion on Drug Safety.2024; 23(7): 917. CrossRef
Posterior reversible encephalopathy syndrome in pregnancy
Vaibhavi Birle, Pradnya Dongargaonkar, Sunil Sharma, Aditi Sandip Gaiwal
MGM Journal of Medical Sciences.2022; 9(2): 246. CrossRef
Delayed Gemcitabine-Induced Posterior Reversible Encephalopathy Syndrome
John R. Schaub, Shou-Ching Tang
The American Journal of the Medical Sciences.2021; 361(6): 795. CrossRef
Delayed Posterior Reversible Leukoencephalopathy Syndrome Triggered by FLOT Chemotherapy
Jordi Gandini, Mario Manto, Nicolas Charette
Frontiers in Neurology.2020;[Epub] CrossRef
First line Immunotherapy for Non-Small Cell Lung Cancer
Nicola J. Nasser, Miguel Gorenberg, Abed Agbarya
Pharmaceuticals.2020; 13(11): 373. CrossRef
Prognostic factors and seizure outcome in posterior reversible encephalopathy syndrome (PRES) in children with hematological malignancies and bone marrow failure: A retrospective monocentric study
Pavlína Danhofer, Michaela Tomečková, Dáša Černá, Danica Zapletalová, Ondřej Horák, Štefánia Aulická, Lenka Juříková, Jiří Domanský, Petra Kovalčíková, Tomáš Pavlík, Jaroslav Štěrba, Hana Ošlejšková
Seizure.2019; 72: 1. CrossRef
PRES in the course of hemato-oncological treatment in children
Katarzyna Musioł, Sylwia Waz, Michał Boroń, Magdalena Kwiatek, Magdalena Machnikowska-Sokołowska, Katarzyna Gruszczyńska, Grażyna Sobol-Milejska
Child's Nervous System.2018; 34(4): 691. CrossRef
Posterior reversible encephalopathy syndrome (PRES) in mesenteric leiomyosarcoma: A case report
Ramy Schoucair, Gregory Nicolas, Rechdi Ahdab, Noha Bejjani, Eddie K. Abdalla
International Journal of Surgery Case Reports.2018; 49: 96. CrossRef
Posterior Reversible Encephalopathy Syndrome in a Patient with Spinal Metastasis
Jin Wook Kim, Ju Ho Jeong
Journal of Neurointensive Care.2018; 1(1): 47. CrossRef
Electrographic patterns in patients with posterior reversible encephalopathy syndrome and seizures
Carlos Kamiya-Matsuoka, Sudhakar Tummala
Journal of the Neurological Sciences.2017; 375: 294. CrossRef
A case report of posterior reversible encephalopathy syndrome in a patient receiving gemcitabine and cisplatin
Hannah Cherniawsky, Neesha Merchant, Micheal Sawyer, Maria Ho
Medicine.2017; 96(8): e5850. CrossRef
Neurological PRESentations in Sickle Cell Patients Are Not Always Stroke: A Review of Posterior Reversible Encephalopathy Syndrome in Sickle Cell Disease
Ziad Solh, Michael S. Taccone, Samantha Marin, Uma Athale, Vicky R. Breakey
Pediatric Blood & Cancer.2016; 63(6): 983. CrossRef
Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study
Carlos Kamiya-Matsuoka, Asif M. Paker, Linda Chi, Ayda Youssef, Sudhakar Tummala, Monica E. Loghin
Journal of Neuro-Oncology.2016; 128(1): 75. CrossRef
Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome
Joan How, Margaret Blattner, Susan Fowler, Andrea Wang-Gillam, Suzanne E. Schindler
The Neurologist.2016; 21(6): 112. CrossRef
Reversible posterior leukoencephalopathy syndrome following combinatorial cisplatin and pemetrexed therapy for lung cancer in a normotensive patient: A case report and literature review
CHANGQING XIE, VOVANTI T. JONES
Oncology Letters.2016; 11(2): 1512. CrossRef
A Unique Case of Rituximab-Related Posterior Reversible Encephalopathy Syndrome in a Heart Transplant Recipient With Posttransplant Lymphoproliferative Disorder
A. Jaiswal, I. Sabnani, D.A. Baran, M.J. Zucker
American Journal of Transplantation.2015; 15(3): 823. CrossRef
Posterior Reversible Encephalopathy Syndrome: A Neurologic Phenomenon in Cancer Patients
Eileen M. Le, Monica E. Loghin
Current Oncology Reports.2014;[Epub] CrossRef
Acute neurological disorders following intraperitoneal administration of cisplatin
Geert A.A.M. Simkens, Monique C.J. Hanse, Ignace H.J.T. de Hingh
International Journal of Gynecology & Obstetrics.2013; 120(3): 291. CrossRef
Gemcitabine-induced posterior reversible encephalopathy syndrome: A case report
Pasquale Cioffi, Lucio Laudadio, Antonio Nuzzo, Maurizio Belfiglio, Fabio Petrelli, Iolanda Grappasonni
Journal of Oncology Pharmacy Practice.2012; 18(2): 299. CrossRef
Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma
Michela Maur, Chiara Tomasello, Antonio Frassoldati, Maria Vittoria Dieci, Elena Barbieri, PierFranco Conte
Journal of Clinical Oncology.2012; 30(6): e76. CrossRef
Reversible Posterior Leukoencephalopathy Syndrome following Sunitinib Therapy: A Case Report and Review of the Literature
Khurum H Khan, Audrey Fenton, Eimer Murtagh, James JA McAleer, Alison Clayton
Tumori Journal.2012; 98(5): e139. CrossRef
Des pathologies encéphaliques à connaître — Syndrome d’encéphalopathie postérieure réversible
S. Legriel, F. Pico, F. Bruneel, G. Troché, J. -P. Bedos
Réanimation.2011; 20(S2): 368. CrossRef
Acute Transverse Myelopathy Probably Related to Intravenous Gemcitabine Plus Cisplatin
Meizuo Zhong, Bin Li, Jing Li
Annals of Pharmacotherapy.2011; 45(4): 544. CrossRef
Posterior reversible encephalopathy syndrome associated with deoxycoformycin and alemtuzumab
T Cooksley, P Haji-Michael
Journal of the Royal College of Physicians of Edinburgh.2011; 41(3): 215. CrossRef
Diagnostic uncertainty around seizures in advanced malignancy
Demiana Lenzi Lewis-Hanna, Gurjeet Pamma
BMJ Case Reports.2011; : bcr0520114265. CrossRef
Case Files of the New York City Poison Control Center: Paradichlorobenzene-Induced Leukoencephalopathy
Stephanie H. Hernandez, Sage W. Wiener, Silas W. Smith
Journal of Medical Toxicology.2010; 6(2): 217. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

A Case of Gemcitabine and Cisplatin Associated Posterior Reversible Encephalopathy Syndrome

Cancer Res Treat. 2009;41(1):53-55. Published online March 31, 2009

DOI: https://doi.org/10.4143/crt.2009.41.1.53

XML Download

Abstract
Introduction
Case Report
Discussion
REFERENCES

A Case of Gemcitabine and Cisplatin Associated Posterior Reversible Encephalopathy Syndrome

Fig. 1 Patchy cortical and subcortical T2 hyperintensity without enhancement, bilateral occipital and parietal lobes (on the day of seizure attack [7/31/2008]).

Fig. 2 Improved state of patchy cortical and subcortical T2 hyperintensity without enhancement since 7/31/2008, bilateral occipital and parietal lobes (10 days after seizure attack [8/11/2008]). (on the day of seizure attack [7/31/2008]).

Fig. 1

Fig. 2

A Case of Gemcitabine and Cisplatin Associated Posterior Reversible Encephalopathy Syndrome